AB928 is a potent and selective dual antagonist of the A_2a and A_2b receptors, which is currently in clinical trials. Here, we report the development of two scalable and practical syntheses of AB928. The first-generation synthesis was used to successfully obtain AB928 in excellent yield and purity to support our preclinical and initial clinical studies. Recently, we have developed a second-generation synthesis of AB928 featuring a palladium-free protocol to access 3-(2-amino-6-chloropyrimidin-4-yl)-2-methylbenzonitrile, a key intermediate in the AB928 synthesis. The new method is scalable, practical, and significantly more cost-effective.

中文翻译：

---

AB928，一个双A的可扩展的和实用的合成发展_2A / A _2B受体拮抗剂

AB928是A _2a和A _2b受体的有效且选择性的双重拮抗剂，目前正在临床试验中。在这里，我们报告AB928的两种可扩展且实用的合成技术的发展。第一代合成用于成功获得具有优异收率和纯度的AB928，以支持我们的临床前和初始临床研究。最近，我们开发了AB928的第二代合成，其特征在于无钯协议可访问3-（2-氨基-6-氯嘧啶-4-基）-2-甲基苄腈，AB928合成中的关键中间体。新方法具有可扩展性，实用性，并且更具成本效益。